At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Mar 14, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...
Mar 12, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained...
Feb 19, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The funds...
Feb 12, 2019
PUR1800 (1 US Patent) and PUR5700 (2 US Patents and 2 EU Patents) Intellectual Property Portfolio Expands Significantly
Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs. These patents expand the...
Feb 8, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors,...